Global Cancer Stem Cells Market - 2022-2029

Market Overview

Cancer stem cells market size is estimated to reach USD million by 2029, growing at a CAGR of 6.7 % during the forecast period (2022-2029).

Cancer stem cells are uncommon immortal cells seen in tumors that give rise to a diverse range of cell types that make up the tumor. These cells have been found in a number of human malignancies and may be employed as cancer therapeutic targets.

Market Dynamics

The factors influencing the global cancer stem cells market are increasing funding for stem cell research and cancer and the growing anti-CSCs therapeutics pipeline.

Increasing funding for stem cell research and cancer research is expected to drive market growth.

The National Cancer Institute (NCI) is the world's largest funder of cancer research. The institute's annual budget is roughly $6.25 billion, as established by Congress. These grants help finance the infrastructure that allows cancer research to continue at NCI and other cancer centers, hospitals, community clinics, and colleges worldwide.

The National Cancer Institute (NCI) contains a variety of divisions and centers that perform research or manage research projects. The NCI had $6.4 billion in funds in FY 2020 (including $195 million in CURES Act funding), up 9.2 percent or $524 million from the previous fiscal year. The American Association for Cancer Research (AACR) is the world's first and biggest cancer research organization dedicated to making cancer a thing of the past. Moreover, CIRM sponsors innovative research initiatives focused on expediting medicines to patients with unmet medical needs as the largest source of financing for stem cell research outside the National Institutes of Health. This includes everything from basic research, such as discovery and translational research, to clinical trials. Hence, the increased funding for cancer research and stem cells is expected to drive market growth in the forecast period.

High costs are expected to hamper the market's growth in the forecast period.

Cellular treatments and other regenerative medicines are gaining traction as potentially transformational contributions to modern medicine but at a hefty price tag. Growing and aging populations are already straining public healthcare costs, and many commercial insurers' budgets are also being pressured. Most payers' cash-flow management systems are not.

Industry Analysis

The cancer stem cells market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.

COVID-19 Impact Analysis

The use of stem cell therapies for COVID-19 is expected to positively impact market growth. For instance, antiviral, antimalarial, and anti-inflammatory drugs are among the treatments now being studied for the treatment of COVID-19 disease. While these treatments can help patients recover and live longer, they do not completely restore the lung damage caused by this disease. Stem cell therapies, and more recently, their released extracellular vesicles (EVs), are emerging as novel and promising treatments that may reduce inflammation while also repairing COVID-19-induced lung damage.

Stem cells presumably exert their immunomodulatory, anti-oxidant, and reparative therapeutic actions through their EVs, which could be useful in people with COVID-19, either alone or combined with other treatment drugs. There are currently 17 clinical trials examining MSCs for the treatment of COVID-19, most of which are administered intravenously, with just one experiment testing MSC-derived exosomes by inhalation. Hence, the demand for stem cell therapies is expected to drive market growth.

Segment Analysis

Stem Cell-based Cancer Therapy segment is expected to hold the largest market share in cancer stem cells market.

The stem cell-based cancer therapy segment accounted for the largest market share in 2021. Stem cell-based cancer therapy is further segmented into autologous SC transplants and allogeneic transplants. Stem cell transplants are treatments that help people who have had their blood-forming stem cells destroyed by heavy doses of chemotherapy or radiation therapy used to treat certain cancers. Blood-forming stem cells are crucial because they differentiate into many types of blood cells. An autologous stem cell transplant replaces diseased or damaged bone marrow with healthy blood stem cells from the recipient's body. An autologous bone marrow transplant is similar to an autologous stem cell transplant. When compared to stem cells from a donor, using cells from one's own body during a stem cell transplant has some advantages. If the body produces enough healthy bone marrow cells, an autologous stem cell transplant may be an option.

These cells can be collected, frozen, and used later. People who require severe doses of chemotherapy and radiation to cure their conditions frequently have autologous stem cell transplants. The bone marrow is likely to be damaged due to these treatments. The damaged bone marrow can be replaced with an autologous stem cell transplant. In contrast, an allogeneic stem cell transplant replaces bone marrow that isn't producing enough healthy blood cells with healthy blood stem cells from a donor. An allogeneic bone marrow transplant is similar to an allogeneic stem cell transplant.

Geographical Analysis

North American region holds the largest market share in the global cancer stem cells market

The growing prevalence of cancer and increasing R&D is expected to drive the market in this region. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, although stem cell research is allowed in the United States, it is subject to funding and usage restrictions. Blood cell-forming adult stem cells found in the bone marrow are currently the only stem cells employed to treat illness. Furthermore, many companies in this region are key players, such as Thermo Fisher Scientific, AbbVie, Inc., Stemline Therapeutics, Inc, STEMCELL Technologies, Inc, and others. In addition, Gamida-Cell Ltd., a U.S.-based next-generation stem cell therapy research and development business, will begin rolling out Biologics License Application (BLA) submissions for omidubicel on January 31, 2022. Omidubicel is a bone marrow stem cell transplant clinically developed for patients with blood malignancies. Gamida-Cell Ltd. stated that the rolling submission was approved following good comments from the type B meeting with the FDA.

Competitive Landscape

Major key players in the cancer stem cells market are Merck KGaA, Thermo Fisher Scientific, Inc., Bionomics, AbbVie, Inc., Stemline Therapeutics, Inc, LONZA, PromoCell GmbH, Miltenyi Biotec, STEMCELL Technologies Inc., BIOTIME, Inc.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

Thermo Fisher Scientific provides optimized solutions for cancer stem cell research-from identification and culturing to genomic and functional analysis.

• Attune NxT Flow Cytometer
• Cell Health Assays
• TaqMan Protein Expression Assay

The global cancer stem cells market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.